Breaking News - Candlesense

Gold Reserve Provides Update on U.S. Government’s Statement of Interest Supporting Venezuelan Opposition Government in Litigation Regarding Validity of 2020 PDVSA Bonds

(GRZ) PEMBROKE, Bermuda--(BUSINESS WIRE)--Gold Reserve Ltd. (TSX.V: GRZ) (BSX: GRZ.BH) (OTCQX: GDRZF) (“Gold Reserve” or the “Company”) announces that on August 29, 2025, the U.S. Government filed ...

How might the resolution of the PDVSA bond validity issue influence Gold Reserve's access to financing and its broader strategic position in the Venezuelan mining sector? What is the expected impact of the litigation outcome on Gold Reserve's share price and market valuation in the short to medium term? How will the U.S. Government's Statement of Interest affect the probability of a favorable outcome for Gold Reserve in the PDVSA bond litigation?

Symbol: GRZ

Litigation

18 days ago

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

(NYSE:NVS) Basel, August 30, 2025 – Novartis today announced positive results from V-DIFFERENCE, a Phase IV study evaluating Leqvio® (inclisiran) compared to placebo, both administered on top of in...

Will the Phase IV V‑DIFFERENCE results trigger an immediate re‑rating or price target adjustment from analysts, and how might that influence short‑term stock volatility? What is the anticipated market share shift for Leqvio versus competing PCSK9 inhibitors and other cholesterol‑lowering therapies in the next 12‑24 months? How will the statistically significant LDL‑C goal achievement and reduced muscle pain side‑effects impact Novartis' projected revenue and earnings guidance for Leqvio?

Symbol: NVS

Clinical trials

18 days ago

Read more globenewswire

FLYW Investors Have Opportunity to Lead Flywire Corporation Securities Fraud Lawsuit

(NASDAQ:FLYW) NEW YORK, Aug. 30, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Flywire Corporation (NASDAQ: FLYW) between February...

When is the lawsuit expected to be resolved, and what are the possible outcomes that could drive the stock's future performance? What is the estimated exposure or potential settlement cost for Flywire, and how does it compare to the company's market capitalization? How could the potential securities fraud lawsuit affect Flywire's short-term stock price and volatility?

Symbol: FLYW

Lawsuits

18 days ago

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

(NASDAQ:ALNY) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outc...

How does the KARDIA Phase 2 data and upcoming Phase 3 trial position zilebesiran against other RNA‑i or cardiovascular‑focused competitors in terms of market share and revenue potential? What are the anticipated timelines for data read‑out and potential FDA/EMA submission, and how could those milestones affect valuation? How will the initiation of the Phase 3 CVOT for zilebesiran influence Alnylam's stock momentum and trading volume?

Symbol: ALNY

Clinical trials

18 days ago

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

(NASDAQ:ALNY) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a...

What timelines and milestones (e.g., trial enrollment, data readout) should traders monitor for price volatility and catalyst events? What are the potential competitive risks from other RNAi or hypertension therapies in development, and how might they influence market share? How will the initiation of a Phase III CVOT for Zilebesiran affect Alnylam's revenue forecasts and valuation multiples?

Symbol: ALNY

Clinical trials

18 days ago

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

(RO) Basel, 30 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardiovascular outcomes trial (CVOT) to evaluate the ...

What are the regulatory, reimbursement, and revenue forecast implications if the trial demonstrates a significant reduction in major adverse cardiovascular events? How does zilebesiran’s efficacy, safety, and RNAi mechanism compare to existing hypertension treatments and competing pipeline candidates from other pharma companies? What is the anticipated timeline, enrollment size, and potential market impact of the Phase III CVOT for zilebesiran on Roche and Alnylam’s valuations?

Symbol: RO

Clinical trials

18 days ago

Read more globenewswire

Rosen Law Firm Encourages Vera Bradley, Inc. Investors to Inquire About Securities Class Action Investigation - VRA

(NASDAQ:VRA) NEW YORK, Aug. 30, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Vera B...

Is there precedent for similar allegations in the fashion accessories sector, and how did those cases influence investor sentiment and share price performance? What potential financial exposure could arise from a possible settlement or judgment, and how would that impact earnings forecasts? How might the securities class action investigation affect Vera Bradley's short‑term stock volatility and liquidity?

Symbol: VRA

Lawsuits

18 days ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

(NASDAQ:AMRN) -- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -...

Are there any upcoming regulatory, reimbursement, or pricing developments that could amplify or constrain revenue growth from the newly emphasized indications? What are the implications of the ESC guideline endorsement for VASCEPA/VAZKEPA's market share versus competing EPA/DHA or PCSK9 therapies? How will the highlighted REDUCE-IT sub‑analyses affect Amarin's valuation and short‑term stock momentum?

Symbol: AMRN

Clinical trials

18 days ago

Read more globenewswire

Bybit x Santiment DeFi Report: Platform Tokens Shine As MNT Sees Over $1M Whale Transactions

(MNT) DUBAI, UAE, Aug. 30, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, has released a DeFi report in collaboration with crypto market intellige...

What could the highlighted performance of platform tokens like MNT mean for the broader DeFi sector, and how might it shift capital allocation between competing Layer‑1 and Layer‑2 tokens? How does the influx of large MNT holders affect the token's on‑chain metrics such as staking participation, supply concentration, and liquidity pools? Will the $1M+ whale transactions in MNT trigger a short‑term price rally or cause sell‑pressure as whales unwind positions?

Symbol: MNT

Defi

18 days ago

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine

(NASDAQ:CYTK) Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol

How does aficamten’s efficacy and safety profile compare to existing HCM therapies and other pipeline candidates from competing biotech firms? What are the anticipated timelines for FDA approval and commercialization of aficamten, and how might that influence the company's revenue projections? How will the positive MAPLE-HCM trial results affect CYTK's short‑term stock momentum and trading volumes?

Symbol: CYTK

Clinical trials

18 days ago

Read more globenewswire